cancer treatment

A new study explains how the loss of genetic material on the Y chromosome may drive cancer development in men. Researchers say age-related loss of parts of the Y chromosome can impair tumour suppression, potentially explaining why certain cancers affect men more severely. The findings could point to new biomarkers and treatment approaches.

New reporting highlights that people who survived cancer in childhood face a significantly elevated risk of serious mental health difficulties in adulthood, including depression, anxiety and other psychiatric conditions. The findings point to long-term psychological effects of early cancer diagnosis and treatment, and renew calls for survivors to receive sustained mental health monitoring and support, not just physical follow-up care, well into their adult lives.

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes in dense cell populations play a decisive role in determining the optimal timing of treatment cycles. The finding addresses treatment resistance, described as one of the key challenges in cancer and antibiotic therapy, and suggests treatment scheduling could be improved by accounting for how densely packed cells interact physically rather than relying on biological factors alone.

Researchers, including Italy's National Institute for Nuclear Physics, report that theoretical physics methods have helped reveal how extra-chromosomal DNA behaves inside tumour cells. These circular DNA fragments, separate from chromosomes, are known to drive cancer growth and drug resistance. Applying physics-based modelling to their molecular mechanisms offers new insight that could inform future cancer research and treatment strategies.

Researchers report that biological characteristics of prostate cancer tumours can help identify which patients are most likely to benefit from hormone therapy. The finding suggests tumour biology could be used to tailor treatment decisions rather than applying hormone therapy uniformly. Details of the study, including sample size and clinical impact, were not provided, but the work points toward more personalised prostate cancer care.

Mount Sinai has announced a collaborative research agreement to evaluate a novel liquid radioembolic agent for treating brain tumors. The therapy would deliver radiation directly to tumor tissue in liquid form, an approach being explored for cancers that are difficult to treat surgically. Details on the partner institution, trial design and timeline have not yet been released, and clinical results remain pending.

Volunteers and advocates with the American Cancer Society's Cancer Action Network visited Capitol Hill to meet with members of Congress, urging support for cancer research funding and patient-focused legislation. The advocacy day brings grassroots concerns about prevention, treatment access, and federal research investment directly to lawmakers, and is part of the organization's ongoing effort to keep cancer policy on the national legislative agenda.

Biotech company Vyriad has begun the first-in-human clinical trial of VV169, an in vivo CAR T therapy that engineers immune cells inside the patient's body rather than in a lab. The early-stage trial marks a first step in testing the safety of the experimental cancer treatment in people, an approach watched closely as it could simplify a cell therapy process that is currently complex and costly.